About Hepatic and glial cell adhesion molecule
Hepatic and glial cell adhesion molecule (HEPACAM) is a protein
from Homo sapiens identified by UniProt accession
Q14CZ8, 416 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Hepatic and glial cell adhesion molecule |
| UniProt accession | Q14CZ8 |
| Gene | HEPACAM |
| Organism | Homo sapiens |
| Length | 416 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (63)
Diseases linked to this target (Open Targets).
- megalencephalic leukoencephalopathy with subcortical cysts · score 0.76
- macrocephaly-autism syndrome · score 0.37
- autism spectrum disorder · score 0.27
- genetic disorder · score 0.19
- Intellectual disability · score 0.11
- hepatocellular carcinoma · score 0.07
- medulloblastoma · score 0.04
- urinary bladder carcinoma · score 0.04
- isolated focal cortical dysplasia type II · score 0.04
- leukodystrophy · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14CZ8-F1 | alphafold | PREDICTED | 72.57 | — |
Amino-acid sequence (416 residues)
MKRERGALSR ASRALRLAPF VYLLLIQTDP LEGVNITSPV RLIHGTVGKS ALLSVQYSST SSDRPVVKWQ LKRDKPVTVV QSIGTEVIGT LRPDYRDRIR LFENGSLLLS DLQLADEGTY EVEISITDDT FTGEKTINLT VDVPISRPQV LVASTTVLEL SEAFTLNCSH ENGTKPSYTW LKDGKPLLND SRMLLSPDQK VLTITRVLME DDDLYSCMVE NPISQGRSLP VKITVYRRSS LYIILSTGGI FLLVTLVTVC ACWKPSKRKQ KKLEKQNSLE YMDQNDDRLK PEADTLPRSG EQERKNPMAL YILKDKDSPE TEENPAPEPR SATEPGPPGY SVSPAVPGRS PGLPIRSARR YPRSPARSPA TGRTHSSPPR APSSPGRSRS ASRTLRTAGV HIIREQDEAG PVEISA
Explore Hepatic and glial cell adhesion molecule with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets